Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference
November 21 2017 - 4:10PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will participate
in a fireside chat at the 29th Annual Piper Jaffray Healthcare
Conference on Tuesday, November 28th at 11:30AM Eastern.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
The fireside chat will be webcast live and may be accessed from
the Event Calendar page of Sucampo's website at
http://www.sucampo.com/investors/events-presentations/. A replay of
the webcast will also be available on the Company's website for
several days after the live event. To ensure a timely connection,
it is recommended that users register at least 15 minutes prior to
the scheduled webcast.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of highly
specialized medicines. Sucampo has a late-stage pipeline of product
candidates in clinical development for orphan disease areas,
including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins
with a specific compositional fingerprint that has been granted
orphan designation in the U.S. and Europe and is in a pivotal Phase
2/3 clinical trial for the treatment of Niemann-Pick Disease Type
C-1, a rare progressive genetic disorder. VTS-270 has also
been granted breakthrough therapy designation in the U.S.
Sucampo has an exclusive option for the North American rights to
CPP-1X/sulindac, which is in Phase 3 development for the treatment
of familial adenomatous polyposis and has been granted orphan drug
designation in the U.S. The company has two marketed products –
AMITIZA and RESCULA. For more information, please visit
www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact:Sucampo Pharmaceuticals, Inc.Silvia
TaylorSenior Vice President, Investor Relations and Corporate
Affairs1-240-223-3718staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024